Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Histologically/cytologically confirmed hepatocellular carcinoma not amenable to curative surgery or loco-regional therapy~2. Age 20 years or older~3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1~4. Child-Pugh score of 7 or less~5. Life expectancy more than 3 months~6. Time interval from last loco-regional therapy more than 4 weeks~7. Written informed consent in accordance with good clinical practice (GCP)~Exclusion criteria:~1. More than one line of prior systemic therapy for metastatic/unresectable hepatocellular carcinoma (HCC)~2. Fibrolamellar HCC~3. Uncontrolled or refractory ascites~4. Inadequate organ function~5. Variceal bleeding within 6 months or the presence of inappropriate varices~6. History of major thrombotic (except portal vein thrombosis) or clinically relevant major bleeding event in the past 6 months~7. Major surgery within 4 weeks~8. Known inherited predisposition to bleeding or thrombosis~9. Significant cardiovascular diseases

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
- Group II (Type: EXPERIMENTAL): patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score

Based on this trial design, predict the completion outcome and termination type (if applicable).